Efficacy and Safety of up to Two Years of Tralokinumab Treatment in Adults of Different Racial Subgroups With Moderate-to-Severe Atopic Dermatitis. J of Skin 2022, 6 (6), s74. https://doi.org/10.25251/skin.6.supp.74.